Key Segmentation:
By Vaccine Type
-
mRNA-Based Vaccines
-
Neoantigen-Based Vaccines
-
Dendritic Cell Vaccines
-
Peptide-Based Vaccines
-
Others
By Cancer Type
-
Melanoma
-
Lung Cancer
-
Breast Cancer
-
Colorectal Cancer
-
Prostate Cancer
-
Others
By Technology Platform
-
mRNA PCV
-
Cell-Based
-
Others
By Treatment Approach
-
Monotherapy
-
Combination Therapy
By End-User
-
Hospitals
-
Cancer Research Centers
-
Biotechnology and Pharmaceutical Companies
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
The Personalized Cancer Vaccine Market is expected to grow at a CAGR of 44.88% from 2026 to 2035.
The Personalized Cancer Vaccine Market was valued at USD 302 million in 2025.
Neoantigen-Based Vaccines dominated the market in 2025 with approximately 48% of revenues, driven by their direct alignment with the precision oncology paradigm, strong clinical pipeline support, and compelling clinical evidence of tumor-specific immune activation with minimal off-target toxicity.
Lung Cancer is expected to grow at the fastest CAGR through 2035, driven by its status as the leading cause of cancer mortality globally creating the largest potential patient population, the growing identification of neoantigen-rich lung cancer subtypes responsive to immunotherapy, and an expanding clinical pipeline of personalised vaccine programs in non-small cell lung cancer.
North America dominated the Personalized Cancer Vaccine Market in 2025, led by the United States with approximately 85% of North American revenues, driven by the world's highest NCI cancer research budget, the most active personalised vaccine clinical development ecosystem, and the most favourable regulatory environment for breakthrough cancer therapy designations.
Get in Touch
